1. Home
  2. RDIB vs AKBA Comparison

RDIB vs AKBA Comparison

Compare RDIB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDIB

Reading International Inc Class B

HOLD

Current Price

$8.51

Market Cap

224.9M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDIB
AKBA
Founded
1937
2007
Country
United States
United States
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.9M
251.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RDIB
AKBA
Price
$8.51
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
3.2K
5.2M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.10
$0.82
52 Week High
$17.40
$4.08

Technical Indicators

Market Signals
Indicator
RDIB
AKBA
Relative Strength Index (RSI) 41.27 49.02
Support Level N/A $0.85
Resistance Level $12.53 $1.56
Average True Range (ATR) 0.48 0.07
MACD -0.02 0.03
Stochastic Oscillator 17.90 66.91

Price Performance

Historical Comparison
RDIB
AKBA

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: